title: Opioid peptide deltorphin II simulates the cardioprotective effect of ischemic preconditioning: role of δ₂-opioid receptors, protein kinase C, and K(ATP) channels.
abstract: The cardioprotective properties of a δ₂-opioid receptor agonist deltorphin II were studied in rats with coronary occlusion and reperfusion. Opioid receptor ligands and inhibitors (glybenclamide, chelerythrine, and 5-hydroxydecanoate) were injected intravenously before ischemia and reperfusion. A δ₂-opioid receptor agonist deltorphin II significantly decreased the infarction zone/risk zone index. This effect was abolished by naltrexone, naloxone methiodide, and δ₂-opioid receptor antagonist naltriben, but not by a δ₁-opioid receptor antagonist BNTX. The infarct-limiting effect of deltorphin II was not observed after inhibition of protein kinase C or blockade of mitochondrial K(ATP) channels.
authors.affiliation: Institute of Cardiology, Siberian Division of the Russian Academy of Medical Sciences, Tomsk, Russia. maslov@cardio.tsu.ru
authors.forename: L N
authors.initials: LN
authors.lastname: Maslov
authors.forename: E I
authors.initials: EI
authors.lastname: Barzakh
authors.forename: A V
authors.initials: AV
authors.lastname: Krylatov
authors.forename: G A
authors.initials: GA
authors.lastname: Chernysheva
authors.forename: T
authors.initials: T
authors.lastname: Krieg
authors.forename: N V
authors.initials: NV
authors.lastname: Solenkova
authors.forename: A Yu
authors.initials: AY
authors.lastname: Lishmanov
authors.forename: S Yu
authors.initials: SY
authors.lastname: Cybulnikov
authors.forename: Y
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D000818:Animals; D053119:Benzophenanthridines / Q000494:pharmacology; D001597:Benzylidene Compounds / Q000627:therapeutic use; D003652:Decanoic Acids / Q000494:pharmacology; D005905:Glyburide / Q000494:pharmacology; D006880:Hydroxy Acids / Q000494:pharmacology; D019157:Ischemic Preconditioning, Myocardial / Q000379:methods*; D008297:Male; D015428:Myocardial Reperfusion Injury / Q000378:metabolism; D009271:Naltrexone / Q000031:analogs & derivatives / Q000627:therapeutic use; D009842:Oligopeptides / Q000627:therapeutic use*; D026902:Potassium Channel Blockers / Q000494:pharmacology; D015221:Potassium Channels / Q000502:physiology*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D017465:Receptors, Opioid, delta / Q000187:drug effects / Q000502:physiology*
chemical_list: D053119:Benzophenanthridines; D001597:Benzylidene Compounds; D003652:Decanoic Acids; D006880:Hydroxy Acids; D009842:Oligopeptides; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D017465:Receptors, Opioid, delta; C068868:naltrindole benzofuran; C060209:deltorphin II, Ala(2)-; C077358:7-benzylidenenaltrexone; D009271:Naltrexone; C052853:5-hydroxydecanoic acid; C016299:chelerythrine; D011493:Protein Kinase C; D005905:Glyburide